Fast-Fail Trial Shows New Approach to Identifying Brain Targets for Clinical Treatments

NIH-funded study identifies receptor as possible target for treating anhedonia

We're now on Instagram! Follow us @NIMHgov NEWS & EVENTS Fast-Fail Trial Shows New Approach to Identifying Brain Targets for Clinical Treatments A first-of-its-kind trial has demonstrated that a receptor involved in the brain's reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders. The results of this innovative fast-fail trial, funded by the National Institute of Mental Health (NIMH), are published in Nature Medicine. Learn more

NIMH Science News

Questions? Contact NIMH!

Director's Messages

SUBSCRIBER SERVICES: Manage Preferences  |  Unsubscribe  |  Help

 

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Mental Health · 6001 Executive Boulevard · Bethesda, MD 20892-9663 · 1-866-615-6464